Predictive utility of blood pressure, waist circumference and body mass index for metabolic syndrome in patients with schizophrenia in Singapore

Early Intervention in Psychiatry

Volumn 7, Issue 2, 2013, Pages 205-209

  Nurjono, Milawaty ^a   Lee, Jimmy ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

Blood pressure; Body mass index (BMI); Metabolic syndrome; Schizophrenia; Waist circumference

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PREDICTIVE VALUE; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SINGAPORE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SINGAPORE; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84877026624     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2012.00384.x     Document Type: Article

References (25)

1. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care 2007; 13: 170-177.
2. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010; 119: 101-109.
3. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia. Br J Psychiatry 2003; 183: 534-539.
4. Gough SCL, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 2005; 19: 47-55.
5. Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res 2010; 123: 234-243.
6. Hasnain M, Fredrickson S, Vieweg W, Pandurangi A. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep 2010; 10: 209-216.
7. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009; 119: 171-179.
8. Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007; 28: 857-864.
9. Simons LA, Simons J, Friedlander Y, McCallum J. Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the metabolic syndrome, and independently from its component variables? the Dubbo Study. Heart Lung Circ 2011; 20: 214-219.
10. De Simone G, Devereux RB, Chinali M etal. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study. Nutr Metab Cardiovas Dis 2009; 19: 98-104.
11. Goff DC, Cather C, Evins E etal. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005; 66: 183-194.
12. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010; 196: 116-121.
13. Auquier P, Lançon C, Rouillon F, Lader M. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf 2007; 16: 1308-1312.
14. Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005; 79: 281-288.
15. Jin H, Meyer JM, Mudaliar S etal. Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patients with schizophrenia. J Clin Psychiatry 2010; 71: 1273-1278.
16. Wang F, Wu S, Song Y etal. Waist circumference, body mass index and waist to hip ratio for prediction of the metabolic syndrome in Chinese. Nutr Metab Cardiovas Dis 2009; 19: 542-547.
17. Lee J, Heng D, Ma S, Chew S-K, Hughes K, Tai ES. The metabolic syndrome and mortality: the Singapore Cardiovascular Cohort Study. Clin Endocrinol 2008; 69: 225-230.
18. Khoo CM, Liew CF, Chew SK, Tai ES. The impact of central obesity as a prerequisite for the diagnosis of metabolic syndrome[ast]. Obesity 2007; 15: 262-269.
19. Lee J, Ma S, Heng D etal. Should central obesity be an optional or essential component of the metabolic syndrome? Diabetes Care 2007; 30: 343-347.
20. Heng D, Ma S, Lee JM etal. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 2006; 186: 367-373.
21. Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care 2004; 8: 508-512.
22. Consultation WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
23. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68: 8-13.
24. Ong SK, Fong CW, Ma S etal. Longitudinal study of the socio-demographic determinants of changes in body weight and waist circumference in a multi-ethnic Asian population. Int J Obes 2009; 33: 1299-1308.
25. Narayanan P, Ong LM, Mahanim O. Do the prevalence and components of metabolic syndrome differ among different ethnic groups? A cross sectional study among obese Malaysian adolescents. Metabol Syndr Relat Disord 2011; 9: 389-395.